The Philippine Economic Zone Authority (PEZA) said over the weekend it released the guidelines for the registration of ...

The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...

The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.

Obtaining the Marketing Authorisation Application (MAA) is a key step in the commercialization of drugs in the EU, and also an important help to promote the global market expansion of pharmaceutical ...

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

Anew Health plans a $20M IPO amid slowing revenue growth and market challenges. Discover insights on its expansion plans and ...

The European Union’s (EU) aggressive environmental regulations, particularly the carbon tax, deforestation rules, and supply ...

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding promises. It's a good economic investment, says the Fund's Peter Sands, into a ...

Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children in Uganda, in an implementation science setting. This new pediatric treatment ...

Arpraziquantel, the new pediatric treatment option, is a 150 mg dispersible tablet designed specifically for children aged three months to six years. It is palatable and easily administered to ...